MacroGenics Closes Solid Tumor Clinical Trial After 7 People Die

Published on :

MacroGenics has closed a phase 2 clinical trial of its anti-cancer antibody enoblituzumab after learning of seven deaths potentially associated with hemorrhagic events. The setback means two of MacroGenics’ three attacks on the protein B7-H3 have hit setbacks, but the biotech is forging ahead with the third candidate. 
Having stopped development of a B7-H3xCD3 bispecific early in 2020, MacroGenics continued to push a monoclonal antibody, enoblituzumab, and antibody-drug conjugate (ADC), MGC018, against the immune checkpoint deeper into the clinic. The biotech moved the monoclonal into a combination phase 2 clinical trial in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) last year.
Now, the study has come to an abrupt halt. MacroGenics closed the clinical trial after seven of the 62 participants died. The deaths were potentially linked to hemorrhagic events, a known risk for SCCHN but one that occurs at a lower rate than seen in the phase 2 study.

Rockville’s MacroGenics Enters Research Collaboration with Sweden’s Alligator Bioscience to Develop a Novel Immunotherapy

Published on :

Under the joint research collaboration agreement, which covers activities from candidate drug generation up until IND-enabling studies, each company will be responsible for its own costs. The parties may continue further development of the resulting bispecific molecule under a separate co-development collaboration and licensing agreement.

Maryland Biomanufacturing Leaders Discuss Challenges, Future Needs at 2020 Bio Innovation Conference

Published on :

The BioHealth Capital Region (BHCR) is known globally as a leading vaccine hub with nearly 20% of the world’s leading vaccine development influencers in Maryland, which is the heart of the BHCR.

BioHealth Capital Region is Entering Period of “Creative Destruction” at Perfect Time

Published on :

BioHealth Capital Region is Entering Period of “Creative Destruction” at Perfect Time March 12, 2019 In 1942, Austrian economist Joseph Schumpeter wrote, “ …industrial mutation—if I may use that biological [….]

These Three Pioneering Women in Bio Share Their Stories at First WIB HERstory Gala

Published on :

Women In Bio (WIB) held their 1st annual HERStory Gala this past December at VisArts in Rockville, MD. With over 100 guests in attendance, and sponsorship from leading companies such as Emergent Biosolutions, Macrogenics, KAI Research and Qiagen, the event honored three pioneering women in the life sciences who have made an impact in the BioHealth Capital region and in their field.